Key result
A 10-year ASCVD risk prediction model incorporating novel kidney and cardiac biomarkers improved discrimination compared to the standard ACC/AHA pooled cohort equations in patients with chronic kidney disease.
Why the study?
Individuals with CKD are at high risk for ASCVD, but no ASCVD risk prediction models had been developed in CKD populations to inform clinical care and prevention.
Do CKD-specific risk prediction models incorporating novel biomarkers improve 10-year ASCVD risk prediction compared to standard ACC/AHA pooled cohort equations in patients with chronic kidney disease?
Cohort (n=2,604)
Yes
Do CKD-specific risk prediction models incorporating novel biomarkers improve 10-year ASCVD risk prediction compared to standard ACC/AHA pooled cohort equations in patients with chronic kidney disease?
In patients with chronic kidney disease, novel 10-year ASCVD risk prediction models incorporating clinical variables and cardiac biomarkers outperformed traditional ACC/AHA pooled cohort equations.
Answers are grounded in this paper and cite their sources.
CKD-specific ASCVD risk models may aid stratification; leaves open need for external validation and outcome trials before adoption.
Background Individuals with CKD may be at high risk for atherosclerotic cardiovascular disease (ASCVD). However, there are no ASCVD risk prediction models developed in CKD populations to inform clinical care and prevention. Methods We developed and validated 10-year ASCVD risk prediction models in patients with CKD that included participants without self-reported cardiovascular disease from the Chronic Renal Insufficiency Cohort (CRIC) study. ASCVD was defined as the first occurrence of adjudicated fatal and nonfatal stroke or myocardial infarction. Our models used clinically available variables and novel biomarkers. Model performance was evaluated based on discrimination, calibration, and net reclassification improvement. Results Of 2604 participants (mean age 55.8 years; 52.0% male) included in the analyses, 252 had incident ASCVD within 10 years of baseline. Compared with the American College of Cardiology/American Heart Association pooled cohort equations (area under the receiver operating characteristic curve [AUC]=0.730), a model with coefficients estimated within the CRIC sample had higher discrimination ( P =0.03), achieving an AUC of 0.736 (95% confidence interval [CI], 0.649 to 0.826). The CRIC model developed using clinically available variables had an AUC of 0.760 (95% CI, 0.678 to 0.851). The CRIC biomarker-enriched model had an AUC of 0.771 (95% CI, 0.674 to 0.853), which was significantly higher than the clinical model ( P =0.001). Both the clinical and biomarker-enriched models were well-calibrated and improved reclassification of nonevents compared with the pooled cohort equations (6.6%; 95% CI, 3.7% to 9.6% and 10.0%; 95% CI, 6.8% to 13.3%, respectively). Conclusions The 10-year ASCVD risk prediction models developed in patients with CKD, including novel kidney and cardiac biomarkers, performed better than equations developed for the general population using only traditional risk factors.
No takes yet. Share an insight, caveat, or question.
Bundy et al. (2022) conducted a cohort in Chronic Kidney Disease (n=2,604). CRIC biomarker-enriched ASCVD risk prediction model vs. ACC/AHA pooled cohort equations was evaluated on 10-year incident ASCVD discrimination (AUC) (AUC 0.771, 95% CI 0.674 to 0.853, p=<0.001). A 10-year ASCVD risk prediction model incorporating novel kidney and cardiac biomarkers improved discrimination compared to the standard ACC/AHA pooled cohort equations in patients with chronic kidney disease.
Synapse has enriched 10 related papers. Consider them for comparative context: